Sunil Pauwaa, MD
Advanced Heart Failure and Transplant Cardiology · Oak Lawn, ILNPI 1710125109
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,325 of the $61,942 with a category attached, or 61.9%. 32 manufacturers reported payments, led by AstraZeneca at 28.0% of the total. Reporting peaked in 2021 at $22,121 and has fallen 92.8% since, to $1,595 in 2025.
Across 387 payments — averaging $160.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- Novartis$16K
- Abbott$10K
- Pfizer$9K
- Terumo Medical Corporation$6K
- Novo Nordisk$660
- plus $4K from 26 others
Across 9 payments — averaging $1785.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$16K
What the payments were for
- Consulting fees$9,82516%
- Speaking & faculty fees$38,32562%
- Travel & lodging$1,9063%
- Food & beverage$11,85719%
- Education$290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $17,338 |
| Novartis | 20 | $15,755 |
| Abbott | 225 | $10,080 |
| Pfizer | 11 | $8,828 |
| Terumo Medical Corporation | 5 | $5,606 |
| Novo Nordisk | 8 | $660 |
| United Therapeutics Corporation | 11 | $520 |
| Johnson & Johnson | 12 | $359 |
| Medtronic | 13 | $331 |
| Abiomed | 8 | $314 |
| Actelion Pharmaceuticals US, Inc. | 3 | $252 |
| Endotronix, Inc. | 2 | $248 |
| Boehringer Ingelheim | 4 | $220 |
| Atricure, Inc. | 1 | $178 |
| Boston Scientific | 3 | $171 |
| Cvrx, Inc. | 3 | $170 |
| Ancora Heart, Inc. | 1 | $166 |
| E.r. Squibb & Sons, L.L.C. | 6 | $113 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $97 |
| Getinge USA Sales, LLC | 3 | $92 |
| Kestra Medical Technology Services, Inc. | 2 | $80 |
| Alnylam Pharmaceuticals Inc. | 3 | $73 |
| Amgen | 3 | $57 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Lexicon Pharmaceuticals, Inc. | 2 | $40 |
| Scpharmaceuticals Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $22 |
| Heartflow, Inc. | 1 | $21 |
| Bayer | 1 | $18 |
| Nuwellis, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Chiesi USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$17,082
- ENTRESTO$15,512
- VYNDAQEL$8,475
- HeartMate 3 Left Ventricular Assist Device$3,800
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$951
- CARDIOMEMS$746
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$178
- Impella$176
- AccuCinch$166
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$149
- CardioMEMS HF System$147
- ORENITRAM$127
- REMODULIN$127
- TYVASO$127
- UPTRAVI$122
- OPSUMIT$122
- JARDIANCE$122
- VIGILANT$121
- HeartWare HVAD$114
- XARELTO$112
How this compares
$61,942 in reported general payments places this provider in the 80th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orenitram ErTreprostinil Diolamine | 99 | $1,380,088 |
| VyndamaxTafamidis | 43 | $1,030,396 |
| AdempasRiociguat | 55 | $753,844 |
| OpsumitMacitentan | 49 | $651,052 |
| Tyvaso DpiTreprostinil | 24 | $561,498 |
| WinrevairSotatercept-Csrk | 30 | $423,624 |
| UptraviSelexipag | 13 | $354,183 |
| EntrestoSacubitril/Valsartan | 206 | $273,588 |
| RemodulinTreprostinil Sodium | 24 | $177,734 |
| EliquisApixaban | 130 | $126,730 |
| JardianceEmpagliflozin | 84 | $108,015 |
| Ambrisentan | 12 | $92,991 |
| FarxigaDapagliflozin Propanediol | 65 | $58,643 |
| Tadalafil | 27 | $19,588 |
| XareltoRivaroxaban | 21 | $17,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $8,828 | $1,157,126173 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $252 | $1,005,23562 claims |
| BayerAdempas | $18 | $753,84455 claims |
| NovartisEntresto | $15,755 | $273,588206 claims |
| United Therapeutics CorporationRemodulin | $520 | $177,73424 claims |
| Boehringer IngelheimJardiance | $220 | $108,01584 claims |
| AstraZenecaFarxiga | $17,338 | $58,64365 claims |
| Johnson & JohnsonXarelto | $359 | $17,79221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Oak Lawn
- Muhyaldee DiaOak Lawn$125K
- Ambar AndradeOak Lawn$35K
- William CottsOak Lawn$8K
- Vinh ChauOak Lawn$7K
- Christopher SciamannaOak Lawn$930
- Maria Rosa CostanzoNaperville$716K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.